New drug combination found effective against coronavirus infection: Study – Naveen Bharat

London: A new drug combination can suppress infection by the SARS-CoV-2 virus, which causes COVID-19, according to a study conducted in animals and cell cultures.
Preliminary Exam Result, Published in Journal virus, found that combined use of antiviral drugs nafamostat And Pegasys meets all availability and efficacy requirements.
“This combination effectively suppresses infection,” said Professor Denis Canov of the Norwegian University of Science and Technology (ntnu)
The researchers said the experiments were conducted in cell cultures and in hamsters.
He noted that this does not necessarily mean that the combination works in humans, but could be a hot tip for researchers who are already testing nafamostat in the fight against Covid-19.
According to the researchers, nafamostat is already in use as a monotherapy against Covid-19 and is being extensively tested in Japan, among other places.
Pegasys is currently primarily used to treat hepatitis C combination Both seem to have a positive effect, he said.
“Both drugs attack a factor in our cells called TMPRSS2, which plays an important role in viral replication,” said Magnar Bjoras, a professor at NTNU.
The researchers noted that only low doses of the combination drug are needed.
“Combining lower doses of drugs can have many clinical benefits. This includes fewer adverse events and better outcomes for patients,” said NTNU Doctoral Research Fellow Aleksandr Inevsky.
Researchers believe the combination drug could save lives and make life easier for patients.
He noted that Nafamostat is relatively cheap, while the downside of Pegasys is its high cost.
“SARS-CoV-2 and its vaccine/immune escape variants remain a serious threat to public health due to the lack of effective, rapidly deployable and widely available therapies,” the study authors said.
“Our study may provide a proactive solution to the ongoing pandemic and potential future coronavirus outbreaks, which are still urgently needed in many parts of the world,” he said.
In addition to NTNU, there are other researchers in the study. Oslo University Hospital, ns University of OsloFrench precision medicine company Oncodesign, both in Norway, the University of Tartu Estonia and Helsink University in Finland.
Back to top button